BioAtla, Inc.

BioAtla is a clinical-stage biopharmaceutical company that discovers and engineers conditionally active antibody therapeutics for the treatment of solid tumor cancers. Utilizing its proprietary Conditionally Active Biologics platform, the company designs therapeutic candidates—including antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies—that selectively target cancer cells in acidic tumor microenvironments while sparing healthy tissues. Key pipeline assets include BA3182, an EpCAM- and CD3-targeting bispecific candidate evaluated in advanced adenocarcinoma, and ozuriftamab vedotin, a ROR2-directed antibody-drug conjugate studied in oropharyngeal squamous cell carcinoma. The firm aims to serve cancer patients by developing oncological therapies that reduce systemic toxicity and expand treatable target antigens.

The company operates without internal manufacturing facilities, outsourcing clinical trial drug supply, filling, packaging, storage, and distribution to third-party contract manufacturers. As of February 1, 2026, its intellectual property portfolio comprises 597 issued patents, 13 allowed applications, and 258 pending applications across multiple jurisdictions. The provided text does not identify headquarters or specific operating countries.

Summary of the business section of BioAtla's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we employed 41 employees.”